Online inquiry

IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7300MR)

This product GTTS-WQ7300MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CSF1R gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001288705.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1436
UniProt ID P07333
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ7300MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13391MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PR-1594804
GTTS-WQ11396MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-575
GTTS-WQ15828MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ7609MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ12428MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NI-0501
GTTS-WQ10563MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY­3074828
GTTS-WQ11473MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ2237MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA aVWF81
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW